SEHK:2696Biotechs
Is Shanghai Henlius Biotech (SEHK:2696) Pricey Or Undervalued After Its Canada Denosumab Launch?
Canadian denosumab launch puts Shanghai Henlius Biotech in focus
Shanghai Henlius Biotech (SEHK:2696) is drawing attention after announcing that its denosumab biosimilars BILDYOS and TUZEMTY are now available in Canada through partner Organon, covering all indications of the reference products.
The launch extends Henlius’s reach beyond its primarily China based revenue by bringing its osteoporosis and oncology supportive care portfolio into a mature biologics market, where Organon holds...